Skip to main content

Grace Therapeutics, Inc.

GRCE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001444192

In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Grace Therapeutics, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of GRCE: Q1 2026 compared with Q2 2026
MeasureQ1 2026Q2 2026Change
Holders3433−1
Shares4.26M3.85M−414.7K (−9.7%)
Value$19.7M$8.74M−$11.0M (−55.7%)

New holders (10)

Institutions that held Grace Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to GRCE in Q2 2026
InstitutionSharesValue% of portfolio
Maven Securities LTD200,000$454.0K0.03%
Cantor Fitzgerald, L. P.100,000$227.0K0.00%
Two Sigma Investments, LP96,890$219.9K0.00%
HRT Financial LP62,691$142.0K0.00%
Susquehanna International Group, LLP49,577$112.5K0.00%
BlackRock, Inc.37,535$85.2K0.00%
Rangeley Capital, LLC26,000$59.0K0.06%
Fundamentun, LLC11,158$25.3K0.00%
Scientech Research LLC10,184$23.1K0.02%
Virtu Financial LLC10,166$23.0K0.00%

Sold out (11)

Institutions that held Grace Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.